Le dosage rapide des peptides natriuretiques cardiaques. Une nouvelle contribution au diagnostic, au suivi therapeutique et au pronostic des affections cardio-vasculaires
Borgoens, Philippe; Pierard, Luc
2003 • In Revue Médicale de Liège, 58 (10), p. 615-20
[en] Only about half of the diagnoses of heart failure are correct. The limitations of clinical judgment and complementary investigations are described in this article. Recently, BNP was found to be a good biological marker of ventricular dysfunction. Rapid and reliable BNP measurement is now available and the clinical value of this peptide was examined in many studies. The role of BNP in the diagnosis and management of heart failure will be increasing.
Disciplines :
Systèmes cardiovasculaire & respiratoire
Auteur, co-auteur :
Borgoens, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Cardiologie
Pierard, Luc ; Université de Liège - ULiège > Département des sciences cliniques > Cardiologie - Pathologie spéciale et réhabilitation
Langue du document :
Français
Titre :
Le dosage rapide des peptides natriuretiques cardiaques. Une nouvelle contribution au diagnostic, au suivi therapeutique et au pronostic des affections cardio-vasculaires
Titre traduit :
[en] Rapid Analysis of Circulating Cardiac Natriuretic Peptides. A New Contribution to the Diagnosis, Regular Treatment and Prognosis of Cardiovascular Diseases
Date de publication/diffusion :
octobre 2003
Titre du périodique :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Maison d'édition :
Université de Liège. Revue Médicale de Liège, Liège, Belgique
Sharpe N, Doughty R.- Epidemiology of heart failure and ventricular dysfunction. Lancet, 1998, 352 (suppl 1), 3-7.
Braunwald, Zipes, Libby, et al.- Heart disease, a textbook of cardiovascular medicine, 5 th ed, Saunders Co, 2001, 534-658.
Trochu JN, Bouhour JB.- L'insuffisance cardiaque de l'adulte. Rev Praticien, 2002, 52, 99-112.
Hokkl, Anderson, Kannel et al.- Survival after onset of congestive heart failure in Framingham heart study subjects. Circulation, 1993, 88, 107-11.
Svendstrup Nielsen L, Svanegaard J, Wiggers P, et al.- The yield of a diagnostic hospital dyspnoea clinic for the primary health care section. J Intern Med, 2001, 250, 422-428.
Cowie MR, Struthers AD, Wood DA, et al.- Value of natriuretic peptides in assesment of patients with possible new heart failure in primary care. Lancet, 1997, 350, 1347-1351
Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology: Remme WJ, Swedberg K.- Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J, 2001, 22, 1527-1560.
Charanjit, Rihal, Kathryn B., et al.- The utility of clinical, electrocardiographic and roentgenographic variables in prediction of left ventricular function. Am J Cardiol, 1995, 75, 220-223.
Maisel AS, Krishnaswamy P, Nowak RM, et al.- Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. New Engl J Med, 2002, 347, 161-167.
Cohen Solal A, Salengro E, Garçon Ph, et al.- L'insuffisance cardiaque diastolique: signes et diagnostic. Presse Méd, 2000, 29, 1889-1893.
Mair J, Hammerer-Lercher A, Puschendorf B, et al.- The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med, 2001, 39, 571-588.
Wilkins MR, Redondo J, Brown LA.- The natriuretic peptide family. Lancet, 1997, 349, 1307-1310.
Baughman KL.- B-type natriuretic peptide, A window to the heart. New Engl J Med, 347, 158-159.
Burnet JC Jr.- Vasopeptidase inhibition: a new concept in blood pressure management. J Hypertens, 1999, 17 (suppl. 1), s 37-s 43.
Haloui M, Arnal JF, Pham I, et al.- Compartimentation fonctionnelle de l'action endocrine des peptides natriurétiques cardiaques. Ann Endocrinol, 2000, 61, 32-40.
Wijbenga JAM, Balk AH, Boomsma F, et al.- Cardiac peptides differ in their response to exercise. Europ Heart J, 1999, 20, 1424-1428.
Pemberton CJ, Johnson ML, Yandle TG, et al.- Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension, 2000, 36, 355-359.
McCullough PA, Nowak RM, McCord J, et al.- B-Type Natriuretic peptide and clinical judgment in emergency diagnosis of heart failure. Circulation, 2002, 106, 416-422.
Quyen Dao, Krishnaswamy P, Kazanegra R, et al.- Utility of B-Natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol, 2001, 37, 379-385.
Davis M, Espiner E, Richards G, et al.- Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet, 1994, 343, 440-444.
Morrison LK, Harrison A, Krishnaswamy P, et al.- Utility of a rapid B-Natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. J Am Coll Cardiol, 2002, 39, 202-209.
Nagaya, Nishikimi T, Okano Y, et al.- Plasma brain natriuretic peptide levels increase in proportion to the extend of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol, 1998, 31, 202-208.
The SOLVD investigators.- Effects of enalapril on mortality and the developpement of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. New Engl J Med, 1992, 327, 685-691.
Maisel A, Koon J, Krishnaswamy P, et al.- Utility of B-Natriuretic peptide as a rapid point of care test for screening patients undergoing echography to determine left ventricular dysfunction. Am Heart J, 2001, 141, 367-374.
Servais PL, Donckier JE, Robert A, et al.- Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure: influences of left ventricular dysfunction and coronary artery disease on cardiac hormonal activation. Eur J Clin Invest, 1998, 28, 636-642.
Mcdonagh TA, Robb SD, Murdoch DR, et al.- Biochemical detection of left ventricular systolic dysfunction, Lancet, 1998, 351, 9-13.
Tsutamoto T, Wada A, Maeda K, et al.- Attenuation of compensation of endogenous cardiac natriuretic peptide systeme in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation, 1997, 96, 509-516.
Sagnella G. A, Measurement and signifiance of circulating natriuretic peptides in cardiovascular disease. Clin Sci, 1998, 95, 519-529.
Richards AM, Nicholls MG, Yandle TG, et al.- Neuroendocrine production of left ventricular function and heart failure after acute myocardial infarction. Heart, 1998, 81, 114-120.
Omland T, Aakvaag A, Bonarjee VV, et al.- Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infraction: comparaison with plasma atrial natriuretic and N-Terminal proatrial natriuretic peptide. Circulation, 1996, 93, 1963-1969.
Van Cheng, Kazanagra R, Garcia A, et al,- A rapid bedsite test for B-Type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol, 2001, 37, 386-391.
